WUXAY News and Press, Wuxi AppTec Co. Ltd. ADR From 03/27/23

2023-03-27 23:00:00 ET Summary Wuxi AppTec’s chemical business doubled last year, but only grew around 40% excluding revenue from Covid-related products and services. The drug outsourcing services company’s net profit fell 47.6% sequentially to 1.44 billion yuan in t...

2023-03-20 09:35:45 ET WuXi AppTec press release ( OTCPK:WUXAY ): FY Non-GAAP EPS of RMB3.18. Revenue of RMB39.35B (+71.8% Y/Y). For further details see: WuXi AppTec Non-GAAP EPS of RMB3.18, revenue of RMB39.35B

WuXi AppTec Reports Record Results in 2022 PR Newswire Revenue Up 71.8% Year-Over-Year to RMB39,355 Million Net Profit Attributable to Owners of the Company Up 72.9% Year-Over-Year to RMB8,814 Million Diluted Earnings Per Share (EPS) Up 63.0% ...

WuXi AppTec Named to the 2022 Dow Jones Sustainability World Index PR Newswire SHANGHAI , Dec. 20, 2022 /PRNewswire/ -- WuXi AppTec, a leading global provider of R&D and manufacturing services that enables the global pharmaceutical and healthcare industry, to...

WuXi AppTec Receives 2022 Global Contract Research, Development and Manufacturing Organization Company of the Year Award from Frost & Sullivan WuXi AppTec Receives 2022 Global Contract Research, Development and Manufacturing Organization Company of the Year Award from Frost ...

WuXi AppTec press release ( OTCPK:WUXAY ): Q3 Non-GAAP EPS of RMB0.84. Revenue of RMB28.39B (+71.9% Y/Y). For further details see: WuXi AppTec Non-GAAP EPS of RMB0.84, revenue of RMB28.39B

WuXi AppTec Reports Record Year-to-Date Results in 2022, Third Quarter Revenue over RMB10 Billion PR Newswire Revenue Up 71.9% Year-Over-Year to RMB28,395 Million Net Profit Attributable to Owners of the Company Up 107.1% Year-Over-Year to RMB7,37...

Summary China pharma company Jinxi Jemincare out-licensed global rights for its androgen receptor degrader to Roche in a $650 million agreement. The oral small-molecule candidate, developed in Jemincare’s R&D center, is currently in preclinical testing. Shanghai IASO Bi...

WuXi STA Opens First High Potency Oral Drug Product Manufacturing Facility PR Newswire New facility expands integrated drug product R&D and manufacturing services to global customers SHANGHAI , Sept. 26, 2022 /PRNewswire/ -- WuXi STA, a leadin...

WuXi STA Opens a New Sterile Lipid Nanoparticle Formulation Facility to Enhance Global CRDMO Services for Customers PR Newswire SHANGHAI , Sept. 9, 2022 /PRNewswire/ -- WuXi STA, a subsidiary of WuXi AppTec, today announced the opening of a new steri...